Diagnostic Challenges and Pathogenetic Differences in Biomass-Smoke-Induced versus Tobacco-Smoke-Induced COPD: A Comparative Review
Diagnostics · 27.09.2024 · 14 (19) · 2154
DOI: 10.3390/diagnostics14192154 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 27.09.2024. Verfasst von Joytri Dutta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Pathobiology of Respiratory Diseases, Cell Biology and Physiology Division, Council of Scientific and Industrial Research (CSIR)-Indian Ins…. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSIR, DST-SERB.
Themen: COPD
Abstract (Originalsprache)
Background
Chronic Obstructive Pulmonary Disease (COPD) is a major global health challenge, primarily driven by exposures to tobacco smoke and biomass smoke. While Tobacco-Smoke-Induced COPD (TSCOPD) has been extensively studied, the diagnostic challenges and distinct pathogenesis of Biomass-Smoke-Induced COPD (BSCOPD), particularly in low- and middle-income countries, remain underexplored.
Objective
To explore the differences in clinical manifestations, pulmonary function, and inflammatory profiles between BSCOPD and TSCOPD and highlight the diagnostic complexities of BSCOPD.
Methods
This review analyzes the current literature comparing BSCOPD with TSCOPD, focusing on distinctive pathophysiological mechanisms, inflammatory markers, and oxidative stress processes.
Results
BSCOPD presents differences in clinical presentation, with less emphysema, smaller airway damage, and higher rates of pulmonary hypertension compared to TSCOPD. BSCOPD is also characterized by bronchial hyperresponsiveness and significant hypoxemia, unlike TSCOPD, which exhibits severe airflow obstruction and emphysema. Additionally, the inflammatory profile of BSCOPD includes distinct mucous hypersecretion and airway remodeling.
Conclusions
The unique genetic, epigenetic, and oxidative stress mechanisms involved in BSCOPD complicate its diagnosis and management. Biomass smoke’s underrecognized impact on accelerated lung aging and exacerbation mechanisms emphasizes the need for targeted research to refine diagnostic criteria and management strategies for BSCOPD. Future directions: Further research should focus on identifying specific biomarkers and molecular pathways to enhance early diagnosis and improve clinical outcomes in populations exposed to biomass smoke.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Molecular Pathobiology of Respiratory Diseases, Cell Biology and Physiology Division, Council of Scientific and Industrial Research (CSIR)-Indian Institute of Chemical Biology (IICB), Kolkata 700091, WB, India.
- Academy of Scientific and Innovative Research (AcSIR), Sector-19, Kamla Nehru Nagar, Ghaziabad 201002, UP, India.
- Department of Respiratory Medicine, JSS Medical College, JSS Academy of Higher Education & Research, Mysuru 570015, KA, India.
ORCID-Profile: Joytri Dutta, Padukudru Anand Mahesh, Ulaganathan Mabalirajan
Förderung
- CSIR
- DST-SERB
Zitieren
APA
Dutta, J., Singh, S., Greeshma, M. V., Mahesh, P. A., & Mabalirajan, U. (2024). Diagnostic Challenges and Pathogenetic Differences in Biomass-Smoke-Induced versus Tobacco-Smoke-Induced COPD: A Comparative Review. Diagnostics, 14(19), 2154. https://doi.org/10.3390/diagnostics14192154
Vancouver
Dutta J, Singh S, Greeshma MV, Mahesh PA, Mabalirajan U. Diagnostic Challenges and Pathogenetic Differences in Biomass-Smoke-Induced versus Tobacco-Smoke-Induced COPD: A Comparative Review. Diagnostics. 2024;14(19):2154. doi:10.3390/diagnostics14192154
BibTeX
@article{Dutta2024,
author = {Dutta, Joytri and Singh, Sabita and Greeshma, Mandya V and Mahesh, Padukudru Anand and Mabalirajan, Ulaganathan},
title = {Diagnostic Challenges and Pathogenetic Differences in Biomass-Smoke-Induced versus Tobacco-Smoke-Induced COPD: A Comparative Review},
journal = {Diagnostics},
year = {2024},
volume = {14},
number = {19},
pages = {2154},
doi = {10.3390/diagnostics14192154}
}
EUVIMED